151 related articles for article (PubMed ID: 33350353)
1. Recent patents in dengue disease management.
K Shahid S
Pharm Pat Anal; 2020 Dec; 9(6):173-185. PubMed ID: 33350353
[TBL] [Abstract][Full Text] [Related]
2. Dengue virus 4: the 'black sheep' of the family?
Lazo L
Expert Rev Vaccines; 2020 Sep; 19(9):807-815. PubMed ID: 32853045
[TBL] [Abstract][Full Text] [Related]
3. Biological characteristics of dengue virus and potential targets for drug design.
Qi RF; Zhang L; Chi CW
Acta Biochim Biophys Sin (Shanghai); 2008 Feb; 40(2):91-101. PubMed ID: 18235970
[TBL] [Abstract][Full Text] [Related]
4. Is Dengvaxia a useful vaccine for dengue endemic areas?
Gubler DJ; Halstead SB
BMJ; 2019 Oct; 367():l5710. PubMed ID: 31582375
[No Abstract] [Full Text] [Related]
5. Current management of severe dengue infection.
Lee TH; Lee LK; Lye DC; Leo YS
Expert Rev Anti Infect Ther; 2017 Jan; 15(1):67-78. PubMed ID: 27786589
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated vaccine: the first clinically approved dengue vaccine?
Fink K; Shi PY
Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
[TBL] [Abstract][Full Text] [Related]
8. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
de Silva AM; Harris E
Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716891
[TBL] [Abstract][Full Text] [Related]
9. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections.
Kitab B; Kohara M; Tsukiyama-Kohara K
Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
[TBL] [Abstract][Full Text] [Related]
12. Dengue vaccine: an update on recombinant subunit strategies.
Martin J; Hermida L
Acta Virol; 2016 Mar; 60(1):3-14. PubMed ID: 26982462
[TBL] [Abstract][Full Text] [Related]
13. Biologics for dengue prevention: up-to-date.
Waickman AT; Newell K; Endy TP; Thomas SJ
Expert Opin Biol Ther; 2023 Jan; 23(1):73-87. PubMed ID: 36417290
[TBL] [Abstract][Full Text] [Related]
14. Prospective human trials with dengue virus vaccines and the NS1 antigen production among vaccine recipients.
Arya SC; Agarwal N
Hum Vaccin; 2011 Dec; 7(12):1394. PubMed ID: 22108041
[No Abstract] [Full Text] [Related]
15. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
16. Dengue Vaccine: Considerations before Rollout in Colombia.
Villabona-Arenas CJ; Ocazionez Jimenez RE; Jimenez Silva CL
PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004653. PubMed ID: 27280803
[No Abstract] [Full Text] [Related]
17. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
Elong Ngono A; Shresta S
Front Immunol; 2019; 10():1316. PubMed ID: 31244855
[TBL] [Abstract][Full Text] [Related]
18. Next generation designer virus-like particle vaccines for dengue.
Shukla R; Ramasamy V; Rajpoot RK; Arora U; Poddar A; Ahuja R; Beesetti H; Swaminathan S; Khanna N
Expert Rev Vaccines; 2019 Feb; 18(2):105-117. PubMed ID: 30587054
[TBL] [Abstract][Full Text] [Related]
19. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy.
Watanabe S; Chan KW; Dow G; Ooi EE; Low JG; Vasudevan SG
Antiviral Res; 2016 Mar; 127():10-9. PubMed ID: 26794905
[TBL] [Abstract][Full Text] [Related]
20. A Multi-Perspective Review on Dengue Research.
Sobhia ME; Ghosh K; Singh A; Sul K; Singh M; Kumar R; Sandeep ; Merugu S; Donempudi S
Curr Drug Targets; 2019; 20(15):1550-1562. PubMed ID: 31339068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
